Structure Therapeutics Inc.
GPCRNASDAQHealthcare● Active
$37.77
+$0.19(+0.51%)
Market Cap$2.2B
P/E Ratio—
52W High$94.9
52W Low$15.8
Structure Therapeutics Inc. (GPCR) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · GPCR · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.14B) | ($0.12B) | ($0.09B) | ($0.05B) | ($0.04B) |
| Depreciation & Amort. | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Stock-Based Comp. | $0.03B | $0.02B | $0.01B | $0.00B | $0.00B |
| Change in Working Capital | ($0.09B) | $0.00B | $0.01B | $0.00B | $0.00B |
| Net Cash from Operations | ($0.22B) | ($0.12B) | ($0.08B) | ($0.05B) | ($0.03B) |
| Investing Activities | |||||
| Capital Expenditure | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Purchases of Investments | ($0.55B) | ($0.70B) | ($0.42B) | ($0.12B) | ($0.00B) |
| Sales of Investments | $0.63B | $0.34B | $0.15B | $0.06B | $0.02B |
| Net Cash from Investing | $0.09B | ($0.36B) | ($0.27B) | ($0.06B) | $0.02B |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Cash from Financing | $0.76B | $0.52B | $0.45B | $0.03B | $0.10B |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.23B) | ($0.12B) | ($0.08B) | ($0.05B) | ($0.03B) |
| FCF Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more Structure Therapeutics Inc. data
About Structure Therapeutics Inc. (GPCR) Cash Flow Statement
Structure Therapeutics Inc. generated operating cash flow of ($0.22B) and free cash flow of ($0.23B) for 2025 — a FCF margin of —. Capital expenditure was ($0.00B).
Frequently asked questions
GPCR · 4 questionsStructure Therapeutics Inc. generated free cash flow of ($0.23B) for 2025, down 91.5% year-over-year.
GPCR free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10